The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 9, 2008, Pages 1059-1064

  Hamilton, C D ^a   Stout, J E ^a   Goodman, P C ^a   Mosher, A ^a   Menzies, R ^b   Schluger, N W ^c   Khan, A ^d   Johnson, J L ^e   Vernon, A N ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c McGill University ^*  (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Chest radiograph; Relapse; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ADULT; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG INTERMITTENT THERAPY; DRUG SENSITIVITY; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SECONDARY ANALYSIS; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; HIV SERONEGATIVITY; HUMANS; MALE; MASS CHEST X-RAY; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RIFAMPIN; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 51149114842     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Corbett E L, Charalambous S, Fielding K, et al. Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis 2003; 188: 1156-1163.
2. Frieden T R, Sterling T R, Munsiff S S, Watt C J, Dye C. Tuberculosis. Lancet 2003; 362: 887-899.
3. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367: 938-940.
4. Aber V R, Nunn A J. Factors affecting relapse following short-course chemotherapy. Bull Int Union Tuberc 1978; 53: 276-280.
5. Tripathy S P. Relapse in tuberculosis. Indian J Tuberc 1981; 28: 45-57.
6. Mallory K F, Churchyard G J, Kleinschmidt I, De Cock K M, Corbett E L. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4: 455-462.
7. Vernon A, Burman W, Benator D, Khan A, Bozeman L, for the Tuberculosis Trials Consortium. Acquired rifamycin mono-resistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847.
8. Quy H T, Lan N T, Borgdorff M W, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard retreatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
9. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
10. Driver C R, Munsiff S S, Li J H, Kundamal N, Osahan S S. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33: 1762-1769.
11. Nettles R E, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38: 731-736.
12. Johnson J L, Okwera A, Vjecha M J, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1: 446-453.
13. The Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-534.
14. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77.
15. American Thoracic Society/Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395.
16. Kleinbaum D G, ed. Logistic regression: a self-learning text. New York City: Springer-Varlay, 1994: pp 191-226.
17. Leung A N. Pulmonary tuberculosis: the essentials. Radiology 1999; 210: 307-322.
18. Perlman D C, el-Sadr W M, Nelson E T, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997; 25: 242-246.
19. Eriki P P, Okwera A, Aisu T, Morrissey A B, Ellner J J, Daniel T M. The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda. Am Rev Respir Dis 1991; 143: 185-187.
20. Elliott A M, Luo N, Tembo G, et al. Impact of HIV on tuberculosis in Zambia: a cross-sectional study. BMJ 1990; 301: 412-415.
21. Goodman P C. Tuberculosis and AIDS. Radiol Clin North Am 1995; 33: 707-717.
22. Graham S, Das G K, Hidvegi R J, et al. Chest radiograph abnormalities associated with tuberculosis: reproducibility and yield of active cases. Int J Tuberc Lung Dis 2002; 6: 137-142.